Medical Cannabis Laws Linked to Modest Drop in Opioid Prescribing for Veterans

Study Finds Correlation Between Medical Cannabis Access and Lower Opioid Prescriptions

Veterans living in states with medical cannabis laws received fewer opioid prescriptions for chronic pain compared to veterans in prohibition states, according to the peer-reviewed study. The research analyzed VA prescription data across multiple years, controlling for demographic and clinical variables to isolate the effect of state cannabis policy.

The reduction was modest but statistically significant. Researchers didn't claim causation. They noted the correlation aligns with prior studies suggesting cannabis substitution for opioid pain management.

Methodology and Data Sources

The study drew on VA electronic health records and state-level policy data to compare opioid prescribing patterns before and after medical cannabis law implementation. Key variables included:

• Opioid prescription volume per patient
• Morphine milligram equivalents (MME) dispensed
• Chronic pain diagnosis codes
• State medical cannabis law effective dates

Researchers controlled for patient age, comorbidities, service-connected disability ratings, and regional prescribing norms.

Implications for VA Policy and Federal Scheduling

The findings arrive as the DEA weighs rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. Veterans advocacy groups have long pressed the VA to permit cannabis recommendations. At minimum, they want the agency to stop penalizing veterans who use state-legal cannabis.

Current VA policy prohibits physicians from recommending medical cannabis, even in states where it's legal. Veterans risk losing pain management services if they test positive for THC.

Veteran Access Barriers Remain

Despite state-level legalization, veterans face unique barriers to cannabis access. Federal employment restrictions complicate matters. So do VA policy prohibitions. Many veterans report using cannabis outside VA care, purchasing from state-licensed dispensaries without physician oversight.

Some state medical cannabis programs explicitly include PTSD, traumatic brain injury, and chronic pain as qualifying conditions. These are conditions disproportionately affecting veterans.

Opioid Substitution Evidence Grows

This study adds to a growing body of research linking cannabis access to reduced opioid use, overdose deaths, and prescription volumes. Prior studies have found:

• States with medical cannabis laws report 25% fewer opioid overdose deaths
• Medicaid and Medicare Part D data show lower opioid prescription fills in legal states
• Patient surveys indicate cannabis substitution for opioids, benzodiazepines, and alcohol

For full background on this research area, see the CannIntel topic hub on cannabis as an opioid alternative.

Limitations and Caveats

The study's authors emphasized that correlation doesn't prove causation and that the observed effect size was modest. Unmeasured variables could account for some of the observed reduction. State-level differences in pain management culture matter. So do opioid prescribing guidelines.

The research also didn't track whether veterans actually used cannabis. It only measured whether they lived in states where it was available.

What to Watch

The DEA's rescheduling decision, expected in 2026, could shift federal policy and potentially open the door for VA cannabis research. Veterans groups are pressing Congress to pass legislation explicitly permitting VA physicians to recommend medical cannabis in legal states. The next legislative vehicle: the FY 2027 VA appropriations bill.